Connect Biopharma Holdings Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
7.7%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$1.06next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents and Short-Term Investments Quarterly46M
Phase 2 Seabreeze STAT Asthma Study Enrollment Status Annually100.0Target: 100%
Remaining Potential Milestone Payments from Simcere Partnership Quarterly110M
Watch Items
- Topline data readout from the Phase 2 Seabreeze STAT Asthma studyTrigger: Early September 2026Action: Evaluate clinical efficacy (FEV1 improvement and safety profile) to determine viability of Phase 3 development.
- Topline data readout from the Phase 2 Seabreeze STAT COPD studyTrigger: Shortly after early September 2026Action: Assess clinical efficacy and safety in COPD patients to support regulatory alignment.
- FDA alignment meeting on Phase 3 program design for rademikibartTrigger: Late 2026Action: Confirm clinical trial protocols and endpoints for pivotal Phase 3 trials in the US.
- NMPA regulatory approval and commercial launch of rademikibart in China by partner SimcereTrigger: Late 2026 / Early 2027Action: Monitor for milestone triggers and initial royalty revenue streams to extend cash runway.
Research as of 19 Jun 2026